Nitin Jain, MD, associate professor in the department of leukemia, University of Texas MD Anderson Cancer Center, is the guest of honor to provide a comprehensive and simplified overview of the major advances in chronic lymphocytic leukemia over the past two decades. Dr. Jain talks mutations and time to treatment, prognostic markers, BTK inhibitors, combination regimens, current research, toxicities, cost, and a host of controversies with trial comparator arms, drug similarities, and MRD.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
